Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 2/20 | 0.74 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.74 |
| ▸ | DHFR | P00374 | 2/20 | 0.61 |
| ▸ | MTR | Q99707 | 1/20 | 0.60 |
| ▸ | GART | P22102 | 6/20 | 0.57 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.57 |
| ▸ | ATIC | P31939 | 4/20 | 0.56 |
| ▸ | TYMS | P04818 | 1/20 | 0.54 |
| ▸ | FPGS | Q05932 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Folitixorin SCHEMBL4108452 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL29616436 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL186747 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL16467076 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL50782 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL3180668 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL4537420 | 0.99 | MTHFD2 (0.73) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL30694324 | 0.99 | MTHFD2 (0.73) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL29556725 | 0.98 | MTHFD2 (0.72) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL9430909 | 0.97 | MTHFD2 (0.70) | MTHFD2MTHFD1DHFRMTRGART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000671-A1 | CONCENTRATED SOLUTIONS COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | MERCK PATENT GMBH (DE) | 2026-01-01 | — | — | US | claimed |
| US-20250360135-A1 | COMPOSITIONS COMPRISING DISODIUM 5,10-METHYLENE-(6R)-TETRAHYDROFOLATE | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | US | claimed |
| US-20250319022-A1 | CONCENTRATED SOLUTIONS COMPRISING SODIUM 5,10-METHYLENE-(6R)-TETRAHYDROFOLATE | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | claimed |
| US-20250319089-A1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | claimed |
| EP-4602365-A2 | METHODS OF ASSESSING METABOLIC FLUX | The Regents of The University of Michigan (US) | 2025-08-20 | — | — | EP | claimed |
| US-12318395-B2 | Ethinyl estradiol-β-cyclodextrin complex and process for preparing thereof | LABORATORIOS LEON FARMA, S.A. (ES) | 2025-06-03 | — | — | US | claimed |
| EP-4536185-A1 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND NACL | Merck Patent GmbH (DE) | 2025-04-16 | — | — | EP | claimed |
| EP-4536188-A1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | Merck Patent GmbH (DE) | 2025-04-16 | — | — | EP | claimed |
| EP-4536184-A1 | CONCENTRATED SOLUTIONS COMPRISING SODIUM 5,10-METHYLENE-(6R)- TETRAHYDROFOLATE | Merck Patent GmbH (DE) | 2025-04-16 | — | — | EP | claimed |
| EP-4536186-A1 | CONCENTRATED SOLUTIONS COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | Merck Patent GmbH (DE) | 2025-04-16 | — | — | EP | claimed |
| US-6011040-A | Use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine | EPROVA AG (CH) | 2000-01-04 | — | — | US | claimed |
| US-5997915-A | NATURAL ISOMERS OF TETRAHYDROFOLIC ACID DERIVATIVES | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1999-12-07 | — | — | US | claimed |
| EP-0877563-A4 | FOOD AND VITAMIN PREPARATIONS CONTAINING THE NATURAL ISOMER OF REDUCED FOLATES | UNIV SOUTH ALABAMA (US) | 1999-06-09 | — | — | EP | claimed |
| EP-0898965-A2 | Use of tetrahydrofolates for modulating the homocysteine level | EPROVA Aktiengesellschaft (CH) | 1999-03-03 | — | — | EP | claimed |
| CN-1209729-A | Food and vitamin products containing natural isomer of reduced folates | UNIV SOUTH ALABAMA (US) | 1999-03-03 | — | — | CN | claimed |
| EP-0877563-A1 | FOOD AND VITAMIN PREPARATIONS CONTAINING THE NATURAL ISOMER OF REDUCED FOLATES | South Alabama Medical Science Foundation (US) | 1998-11-18 | — | — | EP | claimed |
| WO-1997027764-A1 | FOOD AND VITAMIN PREPARATIONS CONTAINING THE NATURAL ISOMER OF REDUCED FOLATES | SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION (US) | 1997-08-07 | — | — | WO | claimed |
| US-5455236-A | Stable aqueous compositions | EPROVA AKTIENGESELLSCHAFT (CH) | 1995-10-03 | — | — | US | claimed |
| EP-0579996-B1 | Inclusion compounds of 5,10-methylenetetrahydrofolic acid and cyclodextrin | EPROVA AG (CH) | 1995-05-03 | — | — | EP | claimed |
| EP-0579996-A1 | Inclusion compounds of 5,10-methylenetetrahydrofolic acid and cyclodextrin | EPROVA Aktiengesellschaft (CH) | 1994-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000671-A1 | CONCENTRATED SOLUTIONS COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | MTHFD1, TYMS, FPGS | MTHFD2 5/4885MTHFD1 1/4885DHFR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.